NURO

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

About Neurometrix Inc.

NeuroMetrix is an innovation-driven company focused on the development and global commercialization of non-invasive medical devices for the diagnosis and treatment of disorders involving the nervous system. The Company has three commercial products. DPNCheck® is a diagnostic device that provides rapid, point-of-care detection of peripheral neuropathies. ADVANCE® is a diagnostic device that provides automated, in-office nerve conduction studies for the evaluation of focal neuropathies. Quell® is a wearable neurostimulation device indicated for symptomatic relief of chronic pain that is available over-the-counter.
CEO
Shai Gozani
Employees
20
Headquarters

1000 Winter St
Waltham, Massachusetts 02451-1436
Phone: 17818909989
www.neurometrix.com

News

NeuroMetrix Inc. (NASDAQ:NURO) Rises 3.82%, But An Additional Surge May Follow.
Nov 03, 2022 17:00pm

In recent trading session, NeuroMetrix Inc. (NASDAQ:NURO) saw 9.21 million shares changing hands at last check today with its beta currently measuring 2.37. Company’s recent per share price level of $1.63 trading at $0.06 or 3.82% at last check today assigns it a market valuation of $11.93M. That most recent trading price of NURO’s stock … NeuroMetrix Inc. (NASDAQ:NURO) Rises 3.82%, But An Additional Surge May Follow. Read More »


Source:Marketing Sentinel
NeuroMetrix Announces Strategic Launch of Quell Fibromyalgia
Nov 03, 2022 13:00pm

WOBURN, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced the strategic launch of its Quell ® Fibromyalgia device through the Pathfinder Program. Quell Fibromyalgia is the first and only medical device authorized by the U.S. Food and Drug Administration (FDA) to help reduce the symptoms of fibromyalgia.


Source:GlobeNewswire
NeuroMetrix, Inc. (NURO) Q3 2022 Earnings Call Transcript
Oct 20, 2022 13:32pm

NeuroMetrix, Inc. (NASDAQ:NASDAQ:NURO) Q3 2022 Earnings Conference Call October 20, 2022, 8:00 am ET Company Participants Thomas Higgins - SVP & CFO Shai Gozani - CEO Conference Call…


Source:Seeking Alpha
NeuroMetrix reports Q3 results
Oct 20, 2022 11:04am

NeuroMetrix press release (NURO): Q3 net loss of $1.6MRevenue of $2M (-4.8% Y/Y).


Source:Seeking Alpha
NeuroMetrix Reports Q3 2022 Financial Results
Oct 20, 2022 11:00am

WOBURN, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and nine-month period ended September 30, 2022. The Company''s mission is to reduce the impact of neurological disorders and pain syndromes on individuals and on population health through innovative non-invasive medical devices.


Source:GlobeNewswire
Earnings Scheduled For October 20, 2022
Oct 20, 2022 09:01am

Companies Reporting Before The Bell • ABB (NYSE: ABB ) is estimated to report quarterly earnings at $0.38 per share on revenue of $7.35 billion. • Nokia (NYSE: NOK ) is expected to report quarterly earnings at $0.10 per share on revenue of $6.32 billion. • Telefonaktiebolaget L M (NASDAQ: ERIC ) is estimated to report quarterly earnings at $0.16 per share on revenue of $6.18 billion. • Quest Diagnostics (NYSE: DGX ) is projected to report quarterly earnings at $2.17 per share on revenue of $2.33 billion. • Banc of California (NYSE: BANC ) is projected to report quarterly earnings at $0.47 per share on revenue of $84.68 million. • Nucor (NYSE: NUE ) is likely to report quarterly earnings at $6.69 per share on revenue of $10.03 billion. • CLPS (NASDAQ: CLPS ) is estimated to report earnings for its Fiscal Year 2022. • Alaska Air Gr (NYSE: ALK ) is likely to report quarterly earnings at $2.40 per share on revenue of $2.82 billion. • NeuroMetrix (NASDAQ: NURO ) is expected to report earnings for its third quarter.


Source:Benzinga
NVIV, APDN and NURO among pre market losers
Oct 13, 2022 13:03pm

Relmada Therapeutics RLMD -79% as depression therapy REL-1017 fails phase 3 trial.T2 Biosystems TTOO -25% on revised annual guidance, executes reverse stock split.Argo…


Source:Seeking Alpha
NeuroMetrix, Inc. Announces Date for Third Quarter 2022 Financial Results Conference Call
Oct 12, 2022 19:47pm

WOBURN, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 third quarter financial results before the opening of the market on Oct 20, 2022. The Company will host a conference call at 8:00 a.m., Eastern Time on Oct 20, 2022 to discuss its financial results as well as business developments affecting the Company.


Source:GlobeNewswire
Dice, Albireo top healthcare gainers; Orthofix, NeuroMetrix lead losers'' pack
Oct 11, 2022 14:02pm

Dice Therapeutics DICE +70%. Albireo Pharma ALBO +15%. Orthofix Medical OFIX -20%. NeuroMetrix (NURO) -17%.


Source:Seeking Alpha
Roblox, SunPower, Borr Drilling among premarket losers'' pack
Oct 11, 2022 12:39pm

Green Giant (GGE) -12%.Argo Blockchain ARBK -12% after mines ~8.5% lower bitcoins in September.NeuroMetrix (NURO) -11%.Fujian Blue Hat Interactive Entertainment Technology (BHAT)…


Source:Seeking Alpha
NeuroMetrix Inc. (NURO) produces promising results
Oct 11, 2022 11:48am

In Monday’s session, NeuroMetrix Inc. (NASDAQ:NURO) marked $2.84 per share, up from $2.83 in the previous session. While NeuroMetrix Inc. has overperformed by 0.35%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NURO fell by -68.09%, with highs and lows ranging from $9.85 to $2.67, whereas […]


Source:US Post News
NURO, CSCW and SNTI are among pre market gainers
Oct 10, 2022 12:16pm

NeuroMetrix (NURO) +24%. scPharmaceuticals (SCPH) +22% Announces $100 Million Debt Financing Agreement with Oaktree.Immunic (IMUX) +14% oversubscribed PIPE financing.Kalera Public…


Source:Seeking Alpha